NMP22在泌尿系统肿瘤中的临床应用研究

为了探讨尿液中核基质蛋白(NMP22)对泌尿系统恶性肿瘤诊断的临床意义.本文应用ELISA测定271例泌尿系恶性肿瘤患者和43例泌尿系良性病变患者尿液NMP22含量.结果表明: 检测NMP22对尿路上皮恶性肿瘤的敏感性为89.2%,特异性为93.3%.尿路上皮恶性肿瘤、非尿路上皮恶性肿瘤和泌尿系良性病变患者, 尿NMP22阳性率分别为: 89.2%、37.2%和34.5%, 其中膀胱移行细胞癌89.5%.泌尿系恶性肿瘤比良性病变阳性率明显增高(P＜0.05),尿路上皮恶性肿瘤比非尿路上皮恶性肿瘤阳性率增高(P＜0.05).另外, 尿中NMP22含量与膀胱移行细胞癌分期、分级和肿瘤生长方式以及瘤体数目均无显著差异(P＞0.05).提示尿液NMP22检测对诊断尿路上皮恶性肿瘤有较高的敏感性, NMP22对泌尿系肿瘤良、恶性鉴别诊断也有一定意义.

Clinical Value of NMP22 in Urine of Patients with Urinary System Tumors

To explore the clinical value of NMP22 in urine of patients with urinary system tumors, the levels of NMP22 in urine of 271 patients with urinary system malignant tumors and 47 patients with urinary system benign tumors were measured by ELISA.Result showed that the sensitivity and specificity of NMP22 for diagnosis of urothelium tumors were 89.2% and 93.3% respectively.The positive rate for urothelium tumors, non-urothelium tumors and other genitourinary benign diseases were 89.2%, 37.2% and 34.5% respectively.The positive rate for bladder transitional cell carcinoma was 89.5%. The positive rate for urinary system malignant tumors was significantly different from that for benign tumors( P <0.05).The positive rate for urothelium tumors was significantly higher than that for non-urothelium tumors( P <0.05).Otherwise, the levels of NMP22 in urine were not correlated with clinical stage, grade, growth mode and tumor volume( P >0.05).Conclusion: NMP22 in urine was high sensitivity for urothelium cancer. NMP22 may be a useful marker for the diagnosis and differentialtion of urinary tumors.